OPVS yields 2000000.00% · ABBV yields 3.12%● Live data
📍 OPVS pulled ahead of the other in Year 1
Combined, OPVS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OPVS + ABBV for your $10,000?
NanoFlex Power Corporation researches, develops, commercializes, and licenses photovoltaic technologies that enable thin film solar products. The company has worldwide license and right to sublicense intellectual property resulting from its sponsored research programs, which have resulted in a portfolio of issued and pending U.S. patents and their foreign counterparts. Its patented and patent-pending technologies include Gallium Arsenide based solar thin films; and organic photovoltaic materials, architectures, and fabrication processes for ultra-thin solar films offering aesthetics, such as semi-transparency and tinting, and highly flexible form factors. The company's technologies are targeted at various applications comprising portable and off-grid power generation, building applied photovoltaics, building integrated photovoltaics, space vehicles and unmanned aerial vehicles, semi-transparent solar power generating glazing or windows, ultra-thin solar films for automobiles or other consumer, and Internet of Things application, including sensors. NanoFlex Power Corporation was founded in 1994 and is based in Scottsdale, Arizona.
Full OPVS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.